AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2001 MAR 28 - (NewsRx.com & NewsRx.net) --
by N.R. Saltmarsh, staff medical writer - A vaccine boosting levels of anti-p53 immunity in colorectal cancer patients could prolong disease-free survival, suggest researchers working in The Netherlands.
"Colorectal carcinoma is commonly associated with mutation and overexpression of p53, making this antigen a potential target for immune intervention," noted S.H. Vanderburg and colleagues.
They used serum samples from patients with resected primary colorectal cancer to study proliferative immunity against the p53 antigen.
The majority of samples showed anti-p53 T helper responses, which lasted up to several years after initial surgery and appeared to be highly sensitive ("Long lasting p53-specific T-cell memory responses in the absence of anti-p53 antibodies in patients with resected primary colorectal cancer," European Journal of Immunology, 2001;31(1):146-155).
"Our data argue that ...
Source: HighBeam Research, Vaccine Targeting p53 Antigen Could Prolong Survival.(Brief Article)